Brief Title
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Official Title
A Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients With B-Cell Non-Hodgkin Lymphoma
Brief Summary
RATIONALE: Biological therapies, such as fusion protein cytokine therapy, may stimulate the
immune system in different ways and stop cancer cells from growing. Monoclonal antibodies,
such as rituximab, can block cancer growth in different ways. Some block the ability of
cancer cells to grow and spread. Others find cancer cells and help kill them or carry
cancer-killing substances to them. Giving fusion protein cytokine therapy together with
rituximab may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of fusion protein
cytokine therapy when given after rituximab in treating patients with B-cell non-Hodgkin
lymphoma.
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (MTD) of DI-Leu16-IL2 (DI-Leu16-IL2
immunocytokine) following peripheral blood B cell depletion with rituximab in patients with
B-cell NHL.
II. To investigate the optimal biological dose (OBD) of DI-Leu16-IL2 following peripheral
blood B cell depletion with rituximab in patients with B-cell NHL, which may differ from the
MTD.
III. To describe the toxicities associated with the proposed DI-Leu16-IL2 regimen.
SECONDARY OBJECTIVES:
I. To evaluate the immunogenicity as measured by the induction of DI-Leu16-IL2-specific
antibodies.
II. To evaluate the pharmacokinetics of DI-Leu16-IL2. III. To document any clinical responses
associated with the proposed therapy and survival endpoints of the enrolled patients.
OUTLINE: This is a dose-escalation study of DI-Leu16-IL2 immunocytokine.
Patients receive DI-Leu16-IL2 immunocytokine IV over 4 hours on 4 consecutive Wednesdays.
Patients with detectable CD20-positive B-cells pretreatment also receive rituximab IV on 4
consecutive Tuesdays.
Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up periodically for 5 years.
Study Phase
Phase 1
Study Type
Interventional
Primary Outcome
Maximum tolerated dose of DI-Leu16-IL2
Secondary Outcome
Immunogenicity as a result of DI-Leu16-IL2 administration
Condition
Anaplastic Large Cell Lymphoma
Intervention
DI-Leu16-IL2 immunocytokine
Study Arms / Comparison Groups
Arm I
Description: Patients receive DI-Leu16-IL2 immunocytokine IV over 4 hours on 4 consecutive Wednesdays. Patients with detectable CD20-positive B-cells pretreatment also receive rituximab IV on 4 consecutive Tuesdays. Treatment repeats every 6-8 weeks for up to a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Biological
Estimated Enrollment
9
Start Date
January 2008
Completion Date
July 2014
Primary Completion Date
July 2014
Eligibility Criteria
Inclusion
- Patients with CD20-expressing B cell NHL that is relapsed or refractory to standard
therapy; CLL/SLL with peripheral blood leukemia/lymphoma cells and high-grade
lymphomas (i.e., lymphoblastic lymphoma/Burkitt lymphoma) are excluded
- Patients must have received prior Rituxan
- Measurable disease; in the absence of lymphadenopathy, splenomegaly with defects or
measurable extramedullary disease is acceptable; however, bone marrow involvement
alone will not be included in the study
- Age >=18 years and <=65 physiologic years of age
- KPS >= 70%
- Life expectancy >= 12 weeks
- Serum creatinine =< 1.5 mg/dl
- Total WBC >= 3000/ul or absolute neutrophil count (ANC) >= 1000/ul
- Lymphocyte count >= 0.2 x 10^3/ul
- Platelet count >= 75,000/ul
- Hematocrit >= 25% or hemoglobin >= 9 g/100 ml
- Alanine aminotransferase (ALT) =< 2.5 x UNL
- Aspartate aminotransferase (AST) =< 2.5 x UNL
- Total bilirubin (TBili) < 1.5 x UNL
- Sodium, potassium, and phosphorus within normal limits
- Chest x ray (CXR) within 4 weeks prior to Day 1 with no evidence of pulmonary
congestion, pleural effusions, pulmonary fibrosis, or significant emphysema; if
results are questionable, subjects would have additional lung function testing to
exclude clinically relevant restriction or obstruction; subjects must have an FEV-1
and DLCO of at least 65% and 50% of expected, respectively
- Electrocardiogram (12-lead ECG)
- Echocardiogram (or MUGA) with normal left ventricular function
- Cardiac stress test (e.g., stress thallium scan, stress echocardiography) with normal
results if subject is suspected to have coronary artery disease
- Fasting blood glucose (FBG) < 160 and hemoglobin (Hgb) A1C < 7% for subjects with
diabetes mellitus (DM) or borderline DM
- Women of procreative potential must have negative pregnancy test within the 2-week
screening phase prior to Cycle 1, and all subjects of procreative potential must use
adequate birth control throughout the study; subjects of procreative potential are
defined as any fertile male, and any female who has experienced menarche and has not
undergone successful surgical sterilization (hysterectomy or bilateral oophorectomy)
or is not post-menopausal, defined as age-related amenorrhea >= 12 months
- Provide written informed consent prior to any screening procedures
Exclusion
- Evidence of CNS lymphoma or lymphomatous meningitis
- Prior treatment with IL-2
- Type I hypersensitivity or anaphylactic reactions to murine proteins or to previous
infusion of rituximab
- Pregnant or lactating female
- An immediate need for palliative radiotherapy or systemic corticosteroid therapy
- Known intercurrent infections (including hepatitis C virus [HCV] and HIV or other
conditions), or clinical evidence of these conditions
- Actively infected with or chronic carriers of hepatitis B virus (HBV) as demonstrated
by positive hepatitis B core antibody (HbcHb) or hepatitis B surface antigen (HbsAg);
(subjects who are sero-positive only, i.e., surface antibody positive [HbsAg], are
permitted)
- Other significant active infection
- Major surgery, chemotherapy, investigational agent, or radiation within 30 days of Day
1
- Uncontrolled hypertension (diastolic >= 100 mmHg) or hypotension (systolic =< 90 mmHg)
- History of repeated and clinically relevant episodes of syncope or other paroxysmal,
ventricular, or other significant arrhythmias
- On ECG: a marked baseline prolongation of QT/QTc interval (> grade 2 QTc interval >
470 milliseconds)
- History of medically significant ascites requiring repetitive paracentesis
- Previous diagnosis of Addison's disease
- Previous diagnosis of autoimmune disease (exceptions: subjects with autoimmune
thyroiditis or vitiligo may be enrolled)
- Organ transplant recipient
- History of prior therapy or a serious, uncontrolled medical disorder that in the
investigator's opinion would impair participation in the study
- Known hypersensitivity to Tween-80 or human immunoglobulin
- Legal incapacity or limited legal capacity
- Patients with bulky lymph nodes (>= 10cm) or marked splenomegaly (i.e., extending into
pelvis or crossing the midline)
- Positive anti-DI-Leu16-IL2 antibody assay (where positive is defined as > 10% of the
radiolabeled DI-Leu16-IL2 reactive with the subject's serum)
Gender
All
Ages
18 Years - 65 Years
Accepts Healthy Volunteers
No
Contacts
Ryotaro Nakamura, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT00720135
Organization ID
03131
Secondary IDs
NCI-2010-01228
Responsible Party
Sponsor
Study Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Study Sponsor
Ryotaro Nakamura, Principal Investigator, City of Hope Medical Center
Verification Date
June 2015